Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

New type of cancer therapy shows promise in patients with advanced leukemia

New type of cancer therapy shows promise in patients with advanced leukemia

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Researchers identify new targets for future CLL therapies

Researchers identify new targets for future CLL therapies

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Findings may guide doctors to choose better therapies for patients with myeloma

Findings may guide doctors to choose better therapies for patients with myeloma

Innovative cell therapy shows highly promising results in pediatric patients with ALL

Innovative cell therapy shows highly promising results in pediatric patients with ALL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Comb-shaped polymers efficiently protect proteins in vivo

Comb-shaped polymers efficiently protect proteins in vivo

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.